Home | Welcome to Contract Pharma   
Last Updated Friday, October 31 2014
Print

Sirona Biochem, Biogalenys in Glycoprotein Pact



Published July 3, 2013
Related Searches: Development Preclinical
Sirona Biochem Corp. has signed a Letter of Intent (LOI) to collaborate with Biogalenys to study Sirona's glycoprotein (cell preservation) technology and to develop preclinical data for multiple targeted applications.
 
Potential applications for Sirona’s cell preservation technology include anti-aging cream, sunscreen/UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation. The three-year collaboration will initially study the technology in cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
 
"We are excited to be creating a second project partnership with Biogalenys,” said Neil Belenkie, chief executive officer of Sirona Biochem. "We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On